Reference tissue uptake of [18F]PSMA-1007 in positron emission tomography of recurrent prostate cancer
Open Access
- 23 April 2026
- journal article
- molecular imaging
- Published by Springer Nature in European Radiology
- Vol. 36 (8) , 6810-6819
Abstract
Introduction: Semi-quantitative uptake measurements are part of the PROMISE framework for PET/CT interpretation of tracers targeting the prostate-specific membrane antigen (PSMA), where tumor uptake is compared to uptake in reference tissues. [18F]PSMA-1007 has primarily hepatobiliary excretion and it is suggested to use spleen as reference tissue instead of liver. The aim of this study is to investigate the normal range and interpatient variability of [18F]PSMA-1007 uptake in reference tissue for prostate cancer patients, with particular focus on the splenic uptake. Materials and methods: A total of 102 [18F]PSMA-1007 PET/CT scans of prostate cancer patients with biochemical recurrence (BCR) from three hospitals were included in the analysis. SUV max and SUV mean measurements were performed in the blood pool, liver, spleen, and parotid glands. Results are reported as median with percentiles [5th, 95th]. Results: For 15/102 (15%) and 20/102 (20%) of the patients, the SUV max and SUV mean , respectively, were higher in the spleen than in the parotid glands. Median SUV max of the reference tissues were 1.2 [0.6, 2.2] for blood, 15.8 [8.9, 26.2] for spleen, and 26.6 [14.5, 40.4] for the parotid glands. Median SUV mean were 11.9 [6.6, 20.7] for spleen and 19.3 [11.2, 32.1] for the parotid glands. Conclusion: In this multicenter cohort of BCR patients, [18F]PSMA-1007 reference tissue uptake is reported in accordance with the PROMISE protocol. A substantial number of patients present with higher uptake in the spleen than in parotid glands, for reasons that are currently unexplained. Care should be taken when interpreting these values until further studies are conducted. Key Points: Question The normal range for [18F]PSMA-1007 uptake values in PROMISE reference tissues are not well documented, challenging standardized lesion categorization in prostate cancer PET interpretation . Findings In a multicenter cohort, splenic [18F]PSMA-1007 uptake exceeded parotid gland uptake in a notable subgroup (15%), leading to situations where PSMA expression scoring according to the PROMISE framework cannot be applied as intended . Clinical relevance Unexpectedly high splenic uptake relative to parotid gland uptake of [18F]PSMA-1007 in some patients may affect lesion categorization; careful interpretation is advised .Keywords
Funding Information
- Trond Mohn stiftelse
This publication has 35 references indexed in Scilit:
- Test–retest repeatability of organ uptake on PSMA‐targeted 18F‐DCFPyL PET/CT in patients with prostate cancerThe Prostate, 2023
- PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0European Journal of Nuclear Medicine and Molecular Imaging, 2023
- E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PETEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA–targeted PET Imaging StudiesEuropean Urology, 2018
- 18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kineticsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesionsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Influence of PET reconstruction technique and matrix size on qualitative and quantitative assessment of lung lesions on [18F]-FDG-PET: A prospective study in 37 cancer patientsEuropean Journal of Radiology, 2017
- F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesionsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012